Organon & Co. (NYSE:OGN) Plans Quarterly Dividend of $0.28

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Tuesday, August 6th, Zacks reports. Shareholders of record on Friday, August 16th will be paid a dividend of 0.28 per share on Thursday, September 12th. This represents a $1.12 dividend on an annualized basis and a yield of 5.75%. The ex-dividend date is Friday, August 16th.

Organon & Co. has a payout ratio of 24.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Organon & Co. to earn $4.31 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 26.0%.

Organon & Co. Price Performance

Shares of OGN traded up $0.84 during mid-day trading on Wednesday, hitting $19.49. 490,147 shares of the stock were exchanged, compared to its average volume of 2,282,178. The firm has a 50-day moving average of $20.82 and a two-hundred day moving average of $19.28. Organon & Co. has a 52-week low of $10.84 and a 52-week high of $24.08. The company has a market cap of $5.01 billion, a PE ratio of 4.56, a price-to-earnings-growth ratio of 1.01 and a beta of 0.85. The company has a debt-to-equity ratio of 181.35, a quick ratio of 1.15 and a current ratio of 1.65.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.08 by $0.04. The company had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.61 billion. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. Organon & Co.’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.31 EPS. On average, equities analysts predict that Organon & Co. will post 4.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on OGN. The Goldman Sachs Group increased their price target on Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Piper Sandler increased their price target on Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, April 29th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.